CSIMarket Company Name, Ticker, Industry, else..
 
Cartesian Therapeutics Inc   (NASDAQ: RNAC)
Other Ticker:  
 
 
Price: $15.9200 $-0.02 -0.125%
Day's High: $16.18 Week Perf: 2.98 %
Day's Low: $ 15.40 30 Day Perf: -16.3 %
Volume (M): 60 52 Wk High: $ 41.87
Volume (M$): $ 952 52 Wk Avg: $19.58
Open: $15.93 52 Wk Low: $12.48



 Market Capitalization (Millions $) 275
 Shares Outstanding (Millions) 17
 Employees 68
 Revenues (TTM) (Millions $) 45
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) 136
 Capital Exp. (TTM) (Millions $) 9

Cartesian Therapeutics Inc


   Company Address: 7495 New Horizon Way Frederick 21703 MD
   Company Phone Number: 348-8698   Stock Exchange / Ticker: NASDAQ RNAC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        10.86% 
BMY   -2.45%    
REGN   -5.68%    
TEVA   -4.68%    
UTHR        0.14% 
VTRS   -4.77%    
• View Complete Report
   



Management Announcement

Cartesian Therapeutics Boosts Talent Acquisition with New Inducement Grant Amidst Steady Revenue Performance

Published Thu, Mar 6 2025 12:05 PM UTC

In a strategic move to attract top-tier talent, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a pioneering biotechnology company focused on mRNA cell therapies for autoimmune diseases, has recently announced the granting of an employment inducement award to a new employee. This initiative underscores the organization s commitment to enhancing human capital, a critical compone...
Shares

Cartesian Therapeutics Strengthens Workforce with Strategic Stock Options Amid Market Resilience,

Published Thu, Feb 6 2025 12:05 PM UTC

Cartesian Therapeutics Reinforces Talent Acquisition with Inducement Grants Amid Market DynamicsFREDERICK, Md., February 6, 2025 Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a prominent player in the clinical-stage biotechnology sector and innovator in mRNA cell therapies for autoimmune diseases, has taken a significant step towards fortifying its workforce. On February 3,...
Shares

Empowering Innovation: Cartesian Therapeutics Expands Team with Strategic Stock Options Amid Market Challenges,

Published Tue, Jan 7 2025 12:05 PM UTC

Frederick, Md. January 07, 2025 In a continuing demonstration of confidence in its strategic direction, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a trailblazer in the development of mRNA cell therapies for autoimmune diseases, has announced the issuance of new employment inducement grants to three promising additions to its team. This move marks another significant s...
Management Announcement

Cartesian Therapeutics Announces New Employment Inducement Grants

Published Wed, Dec 18 2024 12:05 PM UTC

The Growing Landscape of Cartesian Therapeutics: Inducement Awards and Promising Clinic...
Clinical Study

Cartesian Therapeutics to Showcase Promising Phase 2b Descartes-08 Data for Myasthenia Gravis at Upcoming Cell Ther...

Published Thu, Nov 21 2024 12:00 PM UTC

In an exciting development for the field of immunotherapy, Cartesian Therapeutics is set to present updated data from its Phase 2b clinical trial of Descartes-08, a novel therapeutic approach for the treatment of Myasthenia Gravis (MG), at the 2nd Annual Cell Therapy for Autoimmune Disease Summit. The presentation will take place on December 3, 2024, coinciding with a specia...






Cartesian Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com